CSIMarket
 
Merck and Co Inc   (MRK)
 

News




Merck Bolsters Its Oncology Pipeline with KEYTRUDA Approval and Harpoon Acquisition

Merck*s KEYTRUDA and LYNPARZA Combination Falls Short in Treating Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck Expands Oncology Pipeline, Acquires Harpoon Therapeutics and Advances Innovative Treatments for Cancer

Investigational Combination Regimen of Islatravir and Lenacapavir Shows Promising Results in Phase 2 Study, Impacts Gilead and Merck*s Antiviral Portfolio

Merck Receives Positive EU CHMP Opinion for KEYTRUDA in Combination Therapy for Resectable NSCLC, While Discontinuing KEYLYNK-008 Trial for Metastatic Squamous NSCLC

Merck Animal Health to Acquire Elanco*s Aqua Business for $13 Billion

Merck Strengthens Oncology Pipeline with $680 Million Acquisition of Harpoon Therapeutics

FDA Fast-Tracks Merck & Daiichi Sankyo*s Lung Cancer Treatment Amidst Rising Sales and Investment

BRAVECTO*s New Injectable Formulation Takes the Lead: Merck Animal Health Sees Exemplary Financial Growth Amidst Industry Contraction

Merck Halts Promising Lung Cancer Trial as Q3 2023 Revenue Surges Despite Competitors* Struggles

Impressive 45.31% Double-Digit EPS Growth Witnesses Major Pharmaceutical Preparations Company, Merck And Co Inc, during July to September 30, 2023

Observing the second quarter of 2023 results, the Major Pharmaceutical Preparations company*s had marginal contraction in their top-line

Deterioration in EPS by -20.1 % at the Major Pharmaceutical Preparations company over the fiscal interval closing December 31 2022

Significant EPS Deterioration at MRK in the third quarter of 2022









Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com